Showing results (121-130 of 392) with videos related to

Sort By:
Pageof 40
Blood|May 27, 2006
Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemiaThorsten Zenz, Matthias Ritgen, Peter Dreger, et al.
Blood|August 1, 2009
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trialThorsten Zenz, Sonja Häbe, Tina Denzel, et al.
Leukemia|September 30, 2018
Control of chronic lymphocytic leukemia development by clonally-expanded CD8<sup>+</sup> T-cells that undergo functional exhaustion in secondary lymphoid tissuesBola S Hanna, Philipp M Roessner, Haniyeh Yazdanparast, et al.
Bone Marrow Transplantation|July 25, 2020
Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapyTorben Rixecker, Vadim Lesan, Manfred Ahlgrimm, et al.
Cancer Cell|August 18, 2012
Synergy between PI3K signaling and MYC in Burkitt lymphomagenesisSandrine Sander, Dinis P Calado, Lakshmi Srinivasan, et al.
Cancers|March 13, 2024
Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient CareMary Ann Anderson, Renata Walewska, Fidelma Hackett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemiaAlexander Kröber, Johannes Bloehdorn, Sebastian Hafner, et al.
Oncotarget|October 23, 2018
Functional characterization of phospholipase C-γ<sub>2</sub> mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorderClaudia Walliser, Martin Wist, Elisabeth Hermkes, et al.
International Journal of Cancer|October 12, 2005
Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancerStephan Wolf, Daniel Mertens, Armin Pscherer, et al.
The Journal of Biological Chemistry|March 19, 2020
Noncatalytic Bruton's tyrosine kinase activates PLCγ<sub>2</sub> variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cellsMartin Wist, Laura Meier, Orit Gutman, et al.
Pageof 40